Alexandra Rakestraw
Family Medicine · Denver, CONPI 1164008215
Payments from drug & device makers
Across 57 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$320
- Lilly USA, LLC$285
- Gilead$118
- Pfizer$110
- Viiv Healthcare Company$110
- Novo Nordisk$72
- plus $578 from 17 others
What the payments were for
- Food & beverage$1,594100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $320 |
| Lilly USA, LLC | 9 | $285 |
| Gilead | 4 | $118 |
| Pfizer | 5 | $110 |
| Viiv Healthcare Company | 4 | $110 |
| Novo Nordisk | 4 | $72 |
| Astellas Pharma US Inc | 3 | $72 |
| AbbVie | 2 | $66 |
| Amgen | 3 | $63 |
| Eisai Inc. | 2 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| GSK | 2 | $38 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Exact Sciences | 1 | $29 |
| Abiomed | 1 | $26 |
| Echosens North America, Inc. | 1 | $26 |
| Bayer | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Merck | 1 | $19 |
| Cranial Technologies, Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Sonex Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,594 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $6,750 |
| Lamotrigine | 16 | $169 |
| Metformin Hcl | 18 | $146 |
| Lisinopril | 20 | $117 |
| Risperidone | 16 | $105 |
| Amlodipine Besylate | 24 | $98 |
| Pravastatin Sodium | 12 | $80 |
| Simvastatin | 11 | $70 |
| Hydrochlorothiazide | 12 | $66 |
| Escitalopram Oxalate | 11 | $66 |
| Atorvastatin Calcium | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $38 | $6,75011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Mia ScottDenver$993K
- Ethan LazarusDenver$688K
- Judith ShlayDenver$264K
- Mark DeutchmanDenver$258K
- Johnny ShenDenver$182K
- Flory KreutterDenver$118K
- Nathaniel MooreDenver$21K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.